N-Deshydroxyethyl Dasatinib

• CAT Number: R008570
• CAS Number: 910297-51-7
• Molecular Formula: C20H22ClN7OS
• Molecular Weight: 443.954
• Purity: ≥95%
• Synonyms: N-(2-Chloro-6-methylphenyl)-2-[[2-methyl-6-(1-piperazinyl)-4-pyrimidinyl]amino]-5-thiazolecarboxamide; Dasatinib metabolite M4
• Target: Drug Metabolite
• Storage: Store at -20°C
• IUPAC Name: N-(2-chloro-6-methylphenyl)-2-[(2-methyl-6-piperazin-1-ylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxamide
• InChI: InChI=1S/C20H22ClN7OS/c1-12-4-3-5-14(21)18(12)27-19(29)15-11-23-20(30-15)26-16-10-17(25-13(2)24-16)28-8-6-22-7-9-28/h3-5,10-11,22H,6-9H2,1-2H3,(H,27,29)(H,23,24,25,26)
• InChIKey: DOBZFFWLHXORTB-UHFFFAOYSA-N
• SMILES: CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)N4CCNCC4)C

N-Deshydroxyethyl Dasatinib (CAS 910297-51-7) is a metabolite of Dasatinib. It is used in the treatment of cancers and immune diseases. Dasatinib is a Bcr-abl tyrosine kinase inhibitor and an EphA2 receptor antagonist.

Overview of Clinical Research

Dasatinib is a Bcr-abl tyrosine kinase inhibitor and an EphA2 receptor antagonist. It has been granted for thr orphan drug status in Chronic myeloid leukaemia and Precursor cell lymphoblastic leukaemia-lymphoma. Bristol-Myers Squibb and the M.D. Anderson Cancer Center completed a phase I/II trial in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (NCT00566618) in Nov, 2020. 

Reference

1.Trentham, D. R., et al. "Elementary processes of the magnesium ion-dependent adenosine triphosphatase activity of heavy meromysin. A transient kinetic approach to the study of kinases and adenosine triphosphatases and a colorimetric inorganic phosphate assay in situ." Biochemical Journal 126.3 (1972): 635-644.
2.Matsuguchi, Tetsuya, et al. "Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL." Journal of Biological Chemistry 269.7 (1994): 5016-5021.
3.Tokarski, John S., et al. "The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants." Cancer research 66.11 (2006): 5790-5797.